These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 33128190)
1. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190 [TBL] [Abstract][Full Text] [Related]
2. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581 [TBL] [Abstract][Full Text] [Related]
3. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population. da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725 [TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population? Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300 [TBL] [Abstract][Full Text] [Related]
5. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520 [TBL] [Abstract][Full Text] [Related]
8. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
9. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer. Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223 [TBL] [Abstract][Full Text] [Related]
10. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related]
11. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900 [TBL] [Abstract][Full Text] [Related]
14. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations]. Duan RR; Sun LX; Zhao HW Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292 [No Abstract] [Full Text] [Related]
15. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266 [TBL] [Abstract][Full Text] [Related]
16. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693 [TBL] [Abstract][Full Text] [Related]
17. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689 [TBL] [Abstract][Full Text] [Related]
18. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
19. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service. Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109 [TBL] [Abstract][Full Text] [Related]